
The words “sure-fire” and biotechnology stocks rarely go together. This is a sector of the stock market that carries higher-than-average risk. The success of these companies depends on clinical trial results, regulatory decisions, and their ability to scale these drugs once they get approved. Even the best ideas can fail trials or face delays.
Despite the elevated risks, it just takes a single drug reaching FDA approval to generate significant returns for investors. Many of these names start as penny stocks, so betting on a winner is like buying a lucky lottery ticket—and this is what keeps investors looking for opportunities in the biotech space.